Literature DB >> 4119363

The enhanced therapeutic effect of cis-platinum (II) diamminodichloride against L1210 leukemia when combined with cyclophosphamide or 1,2-bis(3,5-dioxopiperazine-1-yl)propane or several other antitumor agents.

R J Woodman, A E Sirica, M Gang, I Kline, J M Venditti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4119363     DOI： 10.1159/000221259

Source DB:  PubMed          Journal:  Chemotherapy        ISSN： 0009-3157            Impact factor:   2.544


× No keyword cloud information.
  9 in total

1.  Combination chemotherapy.

Authors:  T A Connors
Journal:  Proc R Soc Med       Date:  1974-06

2.  In vitro synergism of 4-hydroperoxycyclophosphamide and cisplatin: relevance for bone marrow purging.

Authors:  R H Peters; C S Brandon; L A Avila; O M Colvin; R K Stuart
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

3.  Chemotherapy of the squamous cell lung cancer LC-12 with 5-fluorouracil, cisplatin, carboplatin or iproplatin combinations.

Authors:  E Tapazoglou; L Polin; T H Corbett; M al-Sarraf
Journal:  Invest New Drugs       Date:  1988-12       Impact factor: 3.850

Review 4.  [Cis-diamminedichloroplatinum(II). A new antineoplastic agent derived from the group of heavy metal complexes (author's transl)].

Authors:  R Osieka; C G Schmidt
Journal:  Klin Wochenschr       Date:  1979-12-03

5.  Treatment of gynecological malignancies with a combination of cisplatin, adriamycin and ifosfamide.

Authors:  T Nishida; N Nagasue; M Yakushiji
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

6.  Combination chemotherapy with ifosfamide and cis-dichlorodiammineplatinum (II) in advanced malignant melanoma.

Authors:  R Becher; S Seeber; C G Schmidt
Journal:  J Cancer Res Clin Oncol       Date:  1980       Impact factor: 4.553

7.  Cytocidal and toxic effect of various cytostatic drugs on three ascites tumors of the mouse.

Authors:  E Schäfer; B Maurer-Schultze
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

8.  Hexamethylmelamine, adriamycin, and cyclophosphamide (HAC) versus cis-dichlorodiamineplatinum, adriamycin, and cyclophosphamide (PAC) in advanced ovarian cancer: a randomized clinical trial.

Authors:  C Sessa; G Bolis; N Colombo; M D'Incalci; B Mermillod; I Valente; C Mangioni
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

9.  Preclinical antitumor activity of ethyldeshydroxysparsomycin in combination with cisplatin.

Authors:  H P Hofs; D J Wagener; V De Valk-Bakker; H Van Rennes; D De Vos; W H Doesburg; H C Ottenheijm; W J De Grip
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.